Source comparison
Tesamorelin + Ipamorelin Blend for Women Over 40: Protocol Comparison
Primary Mechanism GHRH receptor agonist. Increases GH pulse amplitude Ghrelin receptor agonist. Increases pulse frequency Dual pathway activation. Amplitude + frequency The blend addresses both components of diminished GH secretion in post-menopausal women Vis
This comparison does not assign a generated winner or score.
- Primary Mechanism
- GHRH receptor agonist. Increases GH pulse amplitude
- Ghrelin receptor agonist. Increases pulse frequency
- Dual pathway activation. Amplitude + frequency
- The blend addresses both components of diminished GH secretion in post-menopausal women
- Visceral Fat Reduction
- 15–20% over 26 weeks (FDA trial data)
- Minimal direct effect. Primarily lean mass preservation
- 18–25% with concurrent muscle retention
- Tesamorelin drives fat loss; ipamorelin prevents muscle catabolism during deficit
- Cortisol Impact
- Minimal elevation (12–15% transient)
- No elevation. Selective GHS-R1a activation
- No net elevation when dosed correctly
- Critical advantage for women with perimenopausal cortisol dysregulation
- Injection Frequency
- Daily (2mg subcutaneous before bed)
- 1–2× daily (200–300mcg per dose)
- Daily (2mg tesamorelin + 200mcg ipamorelin combined)
- Single daily injection improves compliance vs separate dosing
- FDA Approval Status
- Approved for HIV lipodystrophy (Egrifta)
- Research peptide. No FDA approval
- Research combination. Off-label use
- Tesamorelin's FDA approval establishes safety profile; ipamorelin data from Phase 2 trials